Alnylam Pharmaceuticals, Inc. (BMV:ALNY)
Mexico
· Delayed Price · Currency is MXN 8,380.00
-180.00 (-2.10%)
At close: Sep 2, 2025
Alnylam Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 313.75 | -278.16 | -440.24 | -1,131 | -852.82 | Upgrade
|
| Depreciation & Amortization | 55.66 | 56.67 | 54.05 | 44.47 | 89.69 | Upgrade
|
| Loss (Gain) From Sale of Investments | 2.31 | 3.02 | 16.94 | 33.31 | -55.7 | Upgrade
|
| Stock-Based Compensation | 348.24 | 272.08 | 221.68 | 230.65 | 165.72 | Upgrade
|
| Other Operating Activities | 248.92 | 152.15 | 194.46 | 273.84 | 174.24 | Upgrade
|
| Change in Accounts Receivable | -359.96 | -86.55 | -87.94 | -45.6 | -101.8 | Upgrade
|
| Change in Inventory | 8.47 | 13.59 | 18.37 | -34.14 | -26.42 | Upgrade
|
| Change in Accounts Payable | 75.07 | 91.09 | 80.84 | 191.77 | 88.24 | Upgrade
|
| Change in Unearned Revenue | -50.64 | -235.45 | 55.02 | -65.91 | -50.4 | Upgrade
|
| Change in Other Net Operating Assets | -117.72 | 3.23 | -9.03 | -38.51 | -72.45 | Upgrade
|
| Operating Cash Flow | 524.08 | -8.31 | 104.16 | -541.27 | -641.69 | Upgrade
|
| Capital Expenditures | -58.7 | -34.28 | -62.21 | -72.06 | -76.37 | Upgrade
|
| Investment in Securities | 497.18 | -63.25 | -269.7 | 254.61 | -192.56 | Upgrade
|
| Other Investing Activities | -2.15 | -19.32 | -4.44 | -13.19 | -4.36 | Upgrade
|
| Investing Cash Flow | 436.33 | -116.84 | -336.35 | 169.35 | -273.3 | Upgrade
|
| Long-Term Debt Issued | 645.69 | - | - | 1,016 | 500 | Upgrade
|
| Long-Term Debt Repaid | -1,193 | - | - | -880.72 | - | Upgrade
|
| Net Debt Issued (Repaid) | -546.95 | - | - | 135.39 | 500 | Upgrade
|
| Issuance of Common Stock | 250.03 | 302.95 | 147.46 | 259.36 | 246.27 | Upgrade
|
| Other Financing Activities | -8.27 | -8.79 | 24.67 | 31 | 500.85 | Upgrade
|
| Financing Cash Flow | -305.19 | 294.16 | 172.13 | 425.75 | 1,247 | Upgrade
|
| Foreign Exchange Rate Adjustments | 34.94 | -15.24 | 6.39 | -7.43 | -9.02 | Upgrade
|
| Net Cash Flow | 690.16 | 153.77 | -53.67 | 46.4 | 323.11 | Upgrade
|
| Free Cash Flow | 465.38 | -42.59 | 41.95 | -613.33 | -718.07 | Upgrade
|
| Free Cash Flow Margin | 12.53% | -1.89% | 2.29% | -59.12% | -85.05% | Upgrade
|
| Free Cash Flow Per Share | 3.46 | -0.33 | 0.34 | -5.04 | -6.06 | Upgrade
|
| Cash Interest Paid | 218.71 | 67.58 | 32.12 | 45.24 | 24.66 | Upgrade
|
| Cash Income Tax Paid | 21.2 | 9.31 | 2.57 | 2.65 | - | Upgrade
|
| Levered Free Cash Flow | 128.79 | 197.88 | 103.55 | -444.35 | 97.11 | Upgrade
|
| Unlevered Free Cash Flow | 286.68 | 286.54 | 179.32 | -346.87 | 186.5 | Upgrade
|
| Change in Working Capital | -444.78 | -214.08 | 57.26 | 7.62 | -162.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.